

Derwent WPI

(c) 2005 Thomson Derwent. All rights reserved.

014190375

WPI Acc No: 2002-011072/200201

XRAM Acc No: C02-002789

**Medicament for prophylaxis or treatment of cardiac
insufficiency, comprising cholesterol synthesis enzyme inhibitor,
preferably cerivastatin**

Patent Assignee: BAYER AG (FARB)

Inventor: BAUERSACHS J; BISCHOFF H; ERTL G; FRACCAROLLO D

Number of Countries: 095 Number of Patents: 004

Patent Family:

Patent No	Kind	Date	Applicat No	Kind	Date	Week
WO 200178747	A1	20011025	WO 2001EP4135	A	20010411	200201 B
DE 10019143	A1	20011025	DE 1019143	A	20000418	200201
DE 10019272	A1	20011025	DE 1019272	A	20000419	200201
AU 200156278	A	20011030	AU 200156278	A	20010411	200219

Priority Applications (No Type Date): DE 1019272 A 20000419; DE 1019143 A 20000418

Patent Details:

Patent No	Kind	Lan	Pg	Main IPC	Filing Notes
-----------	------	-----	----	----------	--------------

WO 200178747	A1	G	16	A61K-031/70	
--------------	----	---	----	-------------	--

Designated States (National): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

Designated States (Regional): AT BE CH CY DE DK EA ES FI FR GB GH GM GR IE IT KE LS LU MC MW MZ NL OA PT SD SE SL SZ TR TZ UG ZW

DE 10019143	A1			A61K-031/22	
-------------	----	--	--	-------------	--

DE 10019272	A1			A61K-031/505	
-------------	----	--	--	--------------	--

AU 200156278	A			A61K-031/70	Based on patent WO 200178747
--------------	---	--	--	-------------	------------------------------

Abstract (Basic): WO 200178747 A1

NOVELTY - The use of a cholesterol synthesis enzyme (CSE) inhibitor (I) is claimed for the preparation of a medicament for the prophylaxis and treatment of cardiac insufficiency.

ACTIVITY - Cardiant. The effect of cerivastatin (I) was tested in rats having operatively induced myocardial infarction. (Ia) was administered via a pharyngeal sonde at 0.3 mg/kg per day, starting 12 days post-operation, for 12 weeks. At the end of this period the average arterial pressure was 113 mm Hg, the left ventricular systolic pressure 133 mm Hg, the left ventricular end diastolic pressure 13.7 mm Hg and the right arterial pressure 4.0 mm Hg. The corresponding values for placebo-treated rats were 95 mm Hg, 116 mm Hg, 24.1 mm Hg and 6.8 mm Hg; and for placebo-treated, sham-operated rats 125 mm Hg, 148 mm Hg, 5.1 mm Hg and 3.2 mm Hg.

MECHANISM OF ACTION - CSE inhibitor. (I) are especially HMG-CoA reductase inhibitors

USE - (I) (previously used as hypolipemic agents) have now been found to be effective in the prophylaxis and treatment of cardiac insufficiency, e.g. by relieving the heart and improving hemodynamics.

ADVANTAGE - (I) are suitable for long term therapy.

pp; 16 DwgNo 0/0

Technology Focus:

TECHNOLOGY FOCUS - PHARMACEUTICALS - Preferred Components: (I) is a statin, preferably lovastatin, simvastatin, pravastatin, fluvastatin, atorvastatin or especially cerivastatin.

Title Terms: MEDICAMENT; PROPHYLACTIC; TREAT; CARDIAC; INSUFFICIENCY; COMPRISE; CHOLESTEROL; SYNTHESIS; ENZYME; INHIBIT; PREFER

Derwent Class: B02; B03

International Patent Class (Main): A61K-031/22; A61K-031/505; A61K-031/70

International Patent Class (Additional): A61K-031/47; A61P-009/00

File Segment: CPI

Manual Codes (CPI/A-N): B06-D01; B07-A02B; B07-D02; B07-D04C; B14-D05D; B14-D10; B14-F01

Chemical Fragment Codes (M2):

- *01* F012 F013 F014 F015 F016 F431 G013 G100 H4 H402 H482 H5 H581 H6 H601 H641 H7 H721 H8 J0 J011 J1 J171 M1 M113 M210 M211 M213 M232 M240 M272 M281 M282 M311 M315 M321 M332 M342 M344 M371 M373 M391 M413 M431 M510 M521 M531 M540 M782 M904 M905 P522 P616 RA00PD-K RA00PD-T RA00PD-M
- *02* F012 F014 F016 F123 G033 G034 G670 H4 H401 H421 H8 J0 J011 J2 J261 J5 J521 L9 L942 M1 M126 M135 M210 M211 M214 M232 M240 M262 M281 M282 M312 M321 M332 M342 M413 M431 M510 M521 M530 M541 M782 M904 M905 P522 P616 R16653-K R16653-T R16653-M R19716-K R19716-T R19716-M
- *03* F012 F014 F016 F123 G033 G034 G670 H4 H401 H402 H421 H482 H8 J0 J011 J012 J1 J171 J2 J261 J5 J521 L9 L942 M1 M126 M135 M210 M211 M215 M233 M240 M262 M281 M282 M312 M315 M321 M332 M342 M344 M371 M391 M413 M415 M431 M510 M520 M521 M530 M541 M782 M904 M905 P522 P616 R16884-K R16884-T R16884-M
- *04* G033 G034 G670 H4 H403 H461 H482 H8 J0 J012 J1 J171 J2 J261 M210 M211 M214 M232 M240 M262 M281 M315 M321 M332 M344 M371 M391 M415 M431 M510 M520 M530 M541 M782 M904 M905 P522 P616 R18645-K R18645-T R18645-M
- *05* D014 D601 G013 G100 H1 H181 H2 H201 H4 H402 H482 H6 H601 H641 H7 H721 H8 J0 J011 J1 J171 M1 M113 M210 M213 M232 M273 M281 M315 M321 M332 M344 M371 M391 M412 M431 M511 M520 M531 M540 M782 M904 M905 P522 P616 R23348-K R23348-T R23348-M
- *06* F011 F012 F013 F014 F015 F016 F017 F019 F123 F421 G010 G013 G019 G100 H1 H181 H2 H201 H4 H401 H421 H6 H601 H641 H8 J0 J011 J3 J311 J5 J521 L9 L942 M1 M113 M119 M123 M136 M210 M213 M232 M240 M281 M312 M321 M332 M342 M373 M391 M413 M431 M510 M522 M533 M540 M782 M904 M905 P522 P616 RA06AL-K RA06AL-T RA06AL-M

Chemical Fragment Codes (M6):

- *07* M905 P522 P616 R280

Specific Compound Numbers: RA00PD-K; RA00PD-T; RA00PD-M; R16653-K; R16653-T; R16653-M; R19716-K; R19716-T; R19716-M; R16884-K; R16884-T; R16884-M; R18645-K; R18645-T; R18645-M; R23348-K; R23348-T; R23348-M; RA06AL-K; RA06AL-T; RA06AL-M

Key Word Indexing Terms:

- *01* 125347-1-0-0-CL 99623-1-0-0-CL 107036-1-0-0-CL 104598-1-0-0-CL 95489-1-0-0-CL 167146-1-0-0-CL